ResMed: Potentially Undervalued Amid Increasing Sleep Apnea Awareness
- ResMed is potentially undervalued, trading at a 31.65% discount from its 5Y average P/E ratio, with strong market leadership and untapped growth potential in OSA treatment. Projected 10-year EPS growth at 12.5% annually with a P/E of 25 gives a 2034 price target of $529.25 and an implied 10.9% CAGR, with potential for higher returns. Risks include competitive pressures from Philips' market re-entry, technological advances reducing OSA prevalence, and challenges in increasing diagnosis rates, yet ResMed's strong market position supports long-term investment.
- 07/03/2024
|
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
- SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2024 on Thursday, August 1, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
- 07/03/2024
|
4 Top Earnings Growth Stocks to Buy: RMD, BMI, LDOS, IR
- Stocks such as ResMed (RMD), Badger Meter (BMI), Leidos (LDOS) and Ingersoll Rand (IR) are currently exhibiting superb earnings growth.
- 07/02/2024
|
Sound Investments: 3 Stocks to Buy for a Good Night's Rest
- When one thinks about safe stocks to buy, investors generally think of blue-chip large-cap companies such as Berkshire Hathaway (NYSE: BRK-A , NYSE: BRK-B ) or Microsoft (NASDAQ: MSFT ). However, manufacturers of beds, sleep apnea machines and proper lighting are participating in a $585 billion global sleep economy.
- 06/29/2024
|
ResMed Stock Is Down Because of GLP-1 Concerns. It Shouldn't Be.
- Shares of ResMed, a maker of CPAP and other sleep-apnea airway machines, have dropped because of weight-loss developments. It's an overreaction.
- 06/27/2024
|
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
- U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday.
- 06/24/2024
|
Why a Pair of Eli Lilly Clinical Trials Sent ResMed Stock Tumbling
- Shares of medical device maker ResMed (RMD) are tumbling in intraday trading Monday as markets react to a pair of Phase 3 clinical trials from drugmaker Eli Lilly (LLY) released Friday that could have an impact on ResMed's future business.
- 06/24/2024
|
Medical-device makers ResMed and Inspire slump after Lilly's Zepbound trial shows benefits for sleep apnea
- Shares of medical-device makers ResMed Inc. and Inspire Medical Systems Inc. tumbled on Monday after Eli Lilly & Co. said it has applied for regulatory approval of its weight-loss drug Zepbound to include treatment of sleep apnea.
- 06/24/2024
|
Best Momentum Stock to Buy for June 24th
- SCS, BKNIY and RMD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 24, 2024.
- 06/24/2024
|
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again
- ResMed stock and Inspire Medical Systems stock tumbled Monday after Eli Lilly said its weight-loss drug reduced sleep apnea events.
- 06/24/2024
|
ResMed Stock Is Sinking. Blame Lilly's Zepbound Trials for Sleep Apnea.
- Eli Lilly is seeking FDA approval to expand the uses for its weight-loss drug Zepbound to include sleep apnea.
- 06/24/2024
|
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 06/19/2024
|
4 Medical Product Stocks to Buy From a Recovering Industry
- Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.
- 06/19/2024
|
4 GARP Stocks to Scoop up for Maximum Returns
- Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, BAH, BAP and AXP are some stocks that hold promise.
- 06/10/2024
|
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
- SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. Held in Houston, the event brought together scientific and medical experts focused on sleep health.
- 06/10/2024
|
Here's Why ResMed (RMD) is a Strong Momentum Stock
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 06/06/2024
|
3 Reasons Growth Investors Will Love ResMed (RMD)
- ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 05/31/2024
|
Here's Why ResMed (RMD) is a Strong Growth Stock
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 05/31/2024
|
ResMed (RMD) Up 16.3% Since Last Earnings: Will it Continue?
- Investors are optimistic about ResMed (RMD) led by strong growth in the U.S. mask and accessories business and its cloud-connected platforms.
- 05/27/2024
|
Scoop up These 4 GARP Stocks to Receive Handsome Returns
- The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. CSL, RMD, BAH and BAP are some stocks that hold promise.
- 05/24/2024
|
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
- Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA) Prevalence of OSA in the United States expected to increase 26.7% in men and women aged 30 –70 Real-world trends of glucagon-like peptide-1 (GLP-1) receptor agonist and PAP therapy use show patients who were adherent to their GLP-1 medication had higher levels of PAP therapy use than those who were non-adherent to their GLP-1 medication SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- A number of accomplished medical and scientific experts presented critical new research on sleep conditions and their effect on cardiovascular health at the American Thoracic Society International Conference. The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits.
- 05/23/2024
|
Wall Street Analysts See ResMed (RMD) as a Buy: Should You Invest?
- When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
- 05/21/2024
|
Here's Why Investors Should Buy ResMed (RMD) Stock Now
- Investors are optimistic about ResMed's (RMD) potential in digital health and expansion in the international market.
- 05/20/2024
|
Boston Scientific (BSX) mCRM System Study Outcome Favorable
- Boston Scientific Corporation (BSX Quick QuoteBSX - Free Report) recently presented favorable six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM System — the first modular cardiac rhythm management system that consists of the EMBLEM Subcutaneous Implantable Defibrillator or S-ICD System and the EMPOWER Leadless Pacemaker. The findings were concurrently published in the New England Journal of Medicine and presented at the Heart Rhythm Society's annual meeting, Heart Rhythm 2024.The recent development will likely bolster Boston Scientific’s Cardiovascular business.About mCRM SystemThe device is designed to communicate wirelessly to coordinate painless intracardiac anti-tachycardia pacing (ATP) therapy, provide rate-responsive bradycardia pacing support and prevent sudden cardiac death without the use of leads in the heart or under the sternum.The company anticipates FDA approval of the mCRM System in 2025. Study DetailsThe trial assessed not only the safety and functionality of the EMPOWER LP as a stand-alone pacemaker but also the efficacy of the EMBLEM S-ICD System in wirelessly requesting the LP to administer ATP treatment. The trial's results satisfied all predetermined six-month safety and efficacy criteria.The trial's results met all pre-established six-month safety and effectiveness endpoints. They showed that the EMPOWER Leadless Pacemaker was implanted with a major complication-free rate of 97.5%, that communication between the EMBLEM S-ICD System and the EMPOWER Leadless Pacemaker was successful in 98.8% of cases, that anti-tachycardia pacing was successful in 61.3% of cases and that no patient requested that anti-tachycardia pacing or bradycardia pacing be turned off because of pain or discomfort.Study Outcome BenefitsBoston Scientific observed outstanding overall clinical performance of the mCRM System in this trial, including a high rate of successful communication from the S-ICD to the leadless pacemaker and a low rate of serious leadless pacemaker problems. These findings are significant because the high percentages of communication success and pain-free termination of spontaneous arrhythmia episodes suggest a potential upgrade pathway for patients currently implanted with an S-ICD who require ATP or pacing.Image Source: Zacks Investment ResearchInstead of exposing all patients to the risks of more invasive approaches, such as placing leads into the heart or tunneling them under the sternum to provide therapies they may not need, these findings suggest physicians may be able to tailor therapy to the patient's specific needs and health.Industry ProspectsPer a report by Grand View Research, the global cardiac rhythm management devices market size was estimated at $16.43 billion in 2023 and is expected to register a CAGR of 6.3% from 2024 to 2030. The growing prevalence of various cardiovascular diseases, such as arrhythmia and atrial fibrillation, among others.Other Notable HighlightsIn February 2024, Boston Scientific gained the FDA’s approval for the FARAPULSE Pulsed Field Ablation (PFA) system, which is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation. The system represents a unique new alternative to standard-of-care thermal ablation treatment.Earlier in 2023, Boston Scientific completed enrollment in the first phase of the ADVANTAGE AF clinical trial, which is studying the FARAPULSE PFA system for treating patients with drug-refractory, symptomatic, persistent AF. The company also commenced enrollment in a second phase of the study to evaluate the safety and effectiveness of the adjunctive use of the FARAPOINT PFA Catheter for cavotricuspid isthmus ablations — a procedure used to treat atrial flutter. Price PerformanceIn the past year, Boston Scientific shares have appreciated 39.1% compared with the industry’s rise of 1%.Zacks Rank and Other Key PicksBoston Scientific currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks from the broader medical space are Medpace (MEDP Quick QuoteMEDP - Free Report) , ResMed (RMD Quick QuoteRMD - Free Report) and Encompass Health Corporation (EHC Quick QuoteEHC - Free Report) .Medpace, sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2024 earnings per share (EPS) of $3.20. The figure beat the Zacks Consensus Estimate by 30.6%. Revenues of $511 million improved 17.7% from last year’s comparable figure. Medpace has an estimated 2024 earnings growth rate of 26.5% compared with the industry’s 12.3%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 12.8%.ResMed, sporting a Zacks Rank #2, reported a first-quarter 2024 EPS of $2.13, which topped the Zacks Consensus Estimate by 10.9%. Revenues of $1.20 billion surpassed the Zacks Consensus Estimate by 1.9%.RMD has an estimated fiscal 2024 earnings growth rate of 17.9% compared with the industry’s 15.7%. In each of the trailing four quarters, the company delivered an average earnings surprise of 2.8%.Encompass Health, carrying a Zacks Rank #2, reported first-quarter 2024 adjusted EPS of $1.12, surpassing the Zacks Consensus Estimate by 20.4%. Net operating revenues of $1.3 billion topped the Zacks Consensus Estimate by 3.6%.EHC has an estimated long-term earnings growth rate of 15.6% compared with the industry’s 11.7% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.7%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>
- 05/20/2024
|
Here's Why Investors Should Buy ResMed (RMD) Stock Now
- ResMed Inc. (RMD Quick QuoteRMD - Free Report) is gaining from the global supply of its cloud-connected platforms, AirSense10 and AirSense11. The MEDIFOX DAN business contributes to the robust organic growth of the SaaS business, raising optimism. However, escalating debt levels and the competitive landscape are a concern.In the past six months, this Zacks Rank #2 (Buy) stock has gained 44% compared with a 11.7% rise of the industry and a 18.1% increase of the S&P 500 composite.The renowned medical device company has a market capitalization of $32.11 billion. The company’s earnings surpassed estimates in three of the trailing four quarters and missed in another. It has an average earnings surprise of 2.81%.Let’s delve deeper.UpsidesRobust Mask Sales: ResMed continues to see strong demand for its market-leading mask portfolio, gaining from a competitor’s recall.The company continues to witness strong growth in the U.S. mask and accessories business, where resupply programs are powered by its digital health ecosystem, including AirView for physicians, Brightree for home care medical equipment providers and myAir for patients. Outside the United States, the company is focused on developing, launching and scaling its direct outreach and subscription programs to help consumers take control of their health and engage directly in refreshing their masks, tubing, humidifiers and other accessories. Potential in Digital Health: ResMed is progressing across several digital health technology initiatives further to increase the value proposition for its connected healthcare ecosystem. The company’s two key global customer-facing software products — AirView and myAir — are 100% in the cloud.Image Source: Zacks Investment ResearchCurrently, ResMed is investing in a portfolio of artificial intelligence-driven capabilities, as well as customer-facing AI products in the company’s ecosystem. These AI-driven data products will provide personalized suggestions to increase patient therapy adherence and ultimately improve patient outcomes. The company is pleased to see that the early testing feedback in both customer groups has been positive.Increased Focus on International Markets: ResMed continues to invest and expand its presence in high-growth markets like China, South Korea, India, Brazil and many countries in Eastern Europe.Sales in Europe, Asia and other markets increased by 3% in the third quarter of fiscal 2024. Globally, device sales increased by 5%, while masks and other sales increased by 10%. Device sales in the U.S., Canada and Latin America increased by 7% supported by solid ongoing new patient diagnoses. Masks and other sales increased by 12%, reflecting growth in resupply and new patient setups.DownsidesEscalating Debt Level: The company’s high debt level is a concern. As of Mar 31, 2024, long-term debt was $997 million, while the cash and cash equivalents balance was only $238 million. A higher debt level induces higher interest payments, which comes with the risk of failure to pay the same. At the end of third-quarter fiscal 2024, the company has a times-interest-earned ratio of 22.6%, lower than third-quarter fiscal 2024 ratio of 29%. Competitive Landscape: The market for SDB products is highly competitive with respect to product price, features and reliability. ResMed's primary competitors include Philips BV, DeVilbiss Healthcare, Fisher & Paykel Healthcare Corporation Limited, Apex Medical Corporation, BMC Medical Co. Ltd., and regional manufacturers. The disparity between the company's resources and those of its competitors may increase due to consolidation in the healthcare industry.Estimate TrendThe Zacks Consensus Estimate for RMD’s fiscal 2024 earnings per share (EPS) has moved down from $7.43 to $7.64 in the past 90 days.The Zacks Consensus Estimate for the company’s fiscal 2024 revenues is pegged at $4.66 billion, suggesting an increase of 10.5% from the year-ago reported figure.Key PicksSome better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS Quick QuoteHIMS - Free Report) , High Tide (HITI Quick QuoteHITI - Free Report) and Medpace (MEDP Quick QuoteMEDP - Free Report) .Hims & Hers Health, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated 2024 earnings growth rate of a staggering 263.6% compared with the industry’s 18.1%. HIMS’ earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 79.2%. Hims & Hers Health’s shares have rallied 53.4% against the industry’s 25.8% decline in the past year.High Tide, sporting a Zacks Rank #1 at present, has an estimated 2024 earnings growth rate of 100%. HITI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 91.7%.The stock has surged 57.9% compared with the industry’s 1% rise in the past year.Medpace, also sporting a Zacks Rank #1 at present, has an estimated 2024 earnings growth rate of 27.1% compared with the industry’s 13.8%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%.Shares of MEDP have skyrocketed 87.7% compared with the industry’s 6.1% growth in the past year. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>
- 05/20/2024
|
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
- SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024 Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101 Research: 26 ResMed-supported abstracts will be presented at ATS. Full list below.
- 05/16/2024
|
What Makes ResMed (RMD) a New Strong Buy Stock
- ResMed (RMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/16/2024
|
Here is Why Growth Investors Should Buy ResMed (RMD) Now
- ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
- 05/15/2024
|
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 05/15/2024
|
4 Top Stocks to Invest in for Astounding Earnings Growth
- Invest in stocks such as BellRing Brands (BRBR), ResMed (RMD), NVIDIA (NVDA) and Transdigm Group (TDG) for solid earnings growth.
- 05/14/2024
|
U.S. Consumer Sentiment Plummets in May: 5 Safe Stock Picks
- We have narrowed our search to five defensive stocks with strong potential for the rest of 2024. These are: ES, ATO, MKC, TSN, RMD.
- 05/13/2024
|
3 GARP Stocks to Scoop up for Maximum Returns
- Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, BAH and KTB are some stocks that hold promise.
- 05/08/2024
|
4 Safe Bets Amid Growing Concerns Over Delay in Rate Cuts
- Investing in defensive stocks like ResMed Inc. (RMD), Encompass Health Corporation (EHC), New Jersey Resources Corporation (NJR) and Global Water Resources, Inc. (GWRS) would be a wise idea during these times of uncertainty.
- 05/03/2024
|
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 04/30/2024
|
Top Stocks to Buy with Rising EPS Estimates After Earnings
- These companies saw their stocks spike after impressively beating earnings expectations last week and more upside could be ahead considering EPS estimates for fiscal 2024 have trended higher afterwards.
- 04/29/2024
|
Looking for a Growth Stock? 3 Reasons Why ResMed (RMD) is a Solid Choice
- ResMed (RMD) could produce exceptional returns because of its solid growth attributes.
- 04/29/2024
|
Here's Why ResMed (RMD) is a Strong Growth Stock
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 04/29/2024
|
S&P 500 Gains and Losses Today: Resmed Soars Amid Strong Demand for Sleep Devices
- Although the latest Personal Consumption Expenditure (PCE) data showed inflation persisting in March, strong earnings reports from several big tech firms helped major U.S. equities indexes pop higher on Friday.
- 04/26/2024
|
Why ResMed Stock Is Soaring Today
- ResMed easily beat Wall Street's earnings estimates for its fiscal Q3. The company's products are enjoying strong demand.
- 04/26/2024
|
ResMed Soars To Eight-Month High As Quarterly Report Wipes Out Weight-Loss Woes
- ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.
- 04/26/2024
|
ResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand
- ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.
- 04/26/2024
|
ResMed Stock Soars After Strong Earnings. Wall Street Thinks It Can Do Even Better.
- The medical devices company beat expectations for its fiscal third quarter.
- 04/26/2024
|
ResMed Inc. (RMD) Q3 2024 Earnings Call Transcript
- ResMed Inc. (NYSE:RMD ) Q3 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Amy Wakeham - Chief Communications and Investor Relations Officer Mick Farrell - Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Dan Hurren - MST Marquee Laura Sutcliffe - UBS Craig Wong-Pan - RBC David Bailey - Macquarie Anthony Petrone - Mizuho Group Suraj Kalia - Oppenheimer Margaret Kaczor-Andrew - William Blair Gretel Janu - E&P Brett Fishbin - KeyBanc Mike Matson - Needham & Company Lyanne Harrison - Bank of America Steve Wheen - Jarden Saul Hadassin - Barrenjoey Capital Mike Toomey - Jefferies Operator Hello. And welcome to the Q3 Fiscal Year 2024 ResMed Earnings Conference Call.
- 04/25/2024
|
Compared to Estimates, ResMed (RMD) Q3 Earnings: A Look at Key Metrics
- While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 04/25/2024
|
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
- ResMed (RMD) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.92 per share. This compares to earnings of $1.68 per share a year ago.
- 04/25/2024
|
ResMed tops quarterly profit estimates on strong demand for sleep apnea devices
- ResMed beat Wall Street estimates for quarterly profit on Wednesday due to strong demand for its sleep apnea devices, sending shares 9% higher in extended trading.
- 04/25/2024
|
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
- Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
- 04/25/2024
|
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
- Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.
- 04/24/2024
|
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/18/2024
|
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
- One of the pharmaceutical giant's hotter medications tested well for a new indication. It has already attracted much attention for the molecule being studied, as it's used in two FDA-approved treatments already.
- 04/17/2024
|
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
- SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
- 04/04/2024
|
5 Medical Product Stocks to Buy Amid Industry Challenges
- Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.
- 04/02/2024
|
Here's Why Investors Should Buy ResMed (RMD) Stock Now
- Investors are optimistic about ResMed (RMD) led by the strong uptake of the myAir app with Air 11 systems.
- 04/01/2024
|
The 7 Best Stocks to Buy With Your Required Minimum Distribution (RMD)
- Once you reach the age of 73, there's no getting around Required Minimum Distributions (RMDs). Yet while there's no getting around making this compulsory withdrawal from your 401(k) or IRA, consider investing it rather than spending it.
- 03/31/2024
|
ResMed (RMD) Debuts the Smallest Full-Face CPAP Mask AirFit F40
- ResMed's (RMD) new AirFit F40 mask combines the ease and comfort of an ultra-compact, full-face mask with the effectiveness of a traditional over-the-nose, full-face mask.
- 03/07/2024
|
Why Is ResMed (RMD) Down 1.7% Since Last Earnings Report?
- ResMed (RMD) reported earnings 30 days ago. What's next for the stock?
- 02/23/2024
|
Got $1,000? Buy These Hot Growth Stocks Before They Take Off
- ResMed makes medical devices for sleep apnea and COPD, a potential market of over a billion people. DexCom is a market leader in continuous glucose monitoring devices for diabetes patients.
- 02/22/2024
|
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
- Investors are optimistic about ResMed's (RMD) increased adoption of AirSense10 and AirSense11 devices.
- 02/20/2024
|
ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 (Revised)
- ResMed's (RMD) new AirCurve11 series incorporates MyAir and AirView digital health apps to provide maximum comfort and support during therapy.
- 02/16/2024
|
ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device
- ResMed's (RMD) new AirCurve11 series incorporates myAir and AirView digital health apps to provide maximum comfort and support during therapy.
- 02/13/2024
|
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
- The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- 02/05/2024
|
MoneyShow's Best Investment Ideas For 2024: Part 7
- MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income. Part 7 of this series includes Oracle, Petrobras, Polaris, Realty Income and ResMed, among others.
- 02/02/2024
|
Three-Stock Lunch: SoFi, Warner Bros. Discovery and ResMed
- Boris Schlossberg, BK Asset Management, joins 'Power Lunch' to discuss SoFi, Warner Bros. Discovery and ResMed.
- 01/29/2024
|
Here's Why ResMed (RMD) is a Strong Momentum Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 01/26/2024
|
ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand
- ResMed's (RMD) Q2 results reflect cost discipline to support an acceleration in profitability.
- 01/25/2024
|
Why ResMed Stock Is Jumping Today
- ResMed topped consensus Wall Street revenue and earnings estimates with its fiscal Q2 results. The company delivered double-digit-percentage growth across all of its products and services.
- 01/25/2024
|
ResMed Inc. (RMD) Q2 2024 Earnings Call Transcript
- ResMed Inc. (RMD) Q2 2024 Earnings Call Transcript
- 01/24/2024
|
ResMed (RMD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 01/24/2024
|
ResMed (RMD) Tops Q2 Earnings and Revenue Estimates
- ResMed (RMD) came out with quarterly earnings of $1.88 per share, beating the Zacks Consensus Estimate of $1.81 per share. This compares to earnings of $1.66 per share a year ago.
- 01/24/2024
|
ResMed beats estimates on strong sleep apnea device sales
- ResMed beat Wall Street estimates for second-quarter revenue and profit on Wednesday, powered by strong demand for its respiratory devices used to treat sleep apnea.
- 01/24/2024
|
3 Stocks to Buy to Benefit From the Booming Sleep Industry
- Google “How important is sleep?” and you get three billion results.
- 01/23/2024
|
Why ResMed Is One Of My Top Picks In 2024
- I opine RMD is now attractively valued given its long-term stability and its product is highly demanded. ResMed's product is in high demand in the modern obesity epidemic. A new weight loss drug will have little effect on the Company.
- 01/22/2024
|
Stay Ahead of the Game With ResMed (RMD) Q2 Earnings: Wall Street's Insights on Key Metrics
- Evaluate the expected performance of ResMed (RMD) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
- 01/19/2024
|
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
- Investors are optimistic about ResMed (RMD) on strong uptake of the myAir app with AirSense11.
- 01/17/2024
|
Here's Why ResMed (RMD) is a Strong Growth Stock
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 01/17/2024
|
US FDA identifies recall of ResMed's respiratory devices as most serious
- The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of certain respiratory masks made by ResMed as most serious as their use could cause major injuries or death.
- 01/11/2024
|
ResMed: A Buy For Investors Seeking Long-Term Rewards
- ResMed is a profitable company with steady growth and attractive margins, making it a solid investment opportunity. The company operates mainly in the sleep apnea market, which is expected to grow significantly in the coming years. Despite being down, the stock has rebounded and is expected to continue gaining in the future.
- 01/10/2024
|
ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
- SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on Wednesday, January 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
- 01/03/2024
|
ResMed: Down 60% With Tremendous Long-Term Potential
- ResMed's shares have fallen 37% due to struggles with profitability and investor fears of weight loss drugs, but I believe in its long-term potential. The company reported a 16% increase in revenue and strong demand for its products, but margins were a concern. ResMed's three-pillar strategy and market outlook remain robust, and it has a solid balance sheet and healthy cash flow.
- 10/30/2023
|
ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Down
- ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust growth in the mask product portfolio.
- 10/27/2023
|
ResMed Inc. (RMD) Q1 2024 Earnings Call Transcript
- ResMed Inc. (NYSE:RMD ) Q1 2024 Results Conference Call October 26, 2023 4:30 PM ET Company Participants Amy Wakeham - Chief Communications and Investor Relations Officer Mick Farrell - Chief Executive Officer Brett Sandercock - Chief Financial Officer Rob Douglas - President and Chief Operating Officer Conference Call Participants David Bailey - Macquarie David Low - JPMorgan Dan Hurren - MST Chris Cooper - Goldman Sachs Craig Wong-Pan - RBC Sean Laaman - Morgan Stanley Margarette Kaczor - William Blair Steve Wheen - Jarden Saul Hadassin - Barrenjoey Capital Matthew Chevrier - Citi Operator Hello, and welcome to the ResMed First Quarter Fiscal Year 2024 Earnings Conference Call and Webcast [Operator Instructions]. As a reminder, this conference is being recorded.
- 10/26/2023
|
ResMed (RMD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 10/26/2023
|
ResMed (RMD) Beats Q1 Earnings and Revenue Estimates
- ResMed (RMD) came out with quarterly earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.63 per share. This compares to earnings of $1.51 per share a year ago.
- 10/26/2023
|
MedTech Earnings in the Age of Ozempic May Not Be That Bad
- September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.
- 10/17/2023
|
Jim Cramer is weighing out the risks of weight loss drugs
- 'Mad Money' host Jim Cramer takes a deep dive into the impact of obesity drugs on various sectors.
- 10/11/2023
|
ResMed (RMD) Gains From Strong Device Sales Amid Macro Woes
- ResMed's (RMD) respiratory care business continues to drive growth and the adoption of bilevel and other non-invasive ventilator solutions worldwide.
- 10/09/2023
|
ResMed to Report First Quarter Fiscal 2024 Earnings on October 26, 2023
- SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2024 on Thursday, October 26, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
- 10/05/2023
|
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
- Investors continue to be optimistic about ResMed (RMD) due to the core business' performance and sustained growth in the SaaS business.
- 10/03/2023
|
Will ResMed Stock Rebound To Its Pre-Inflation Shock Highs Of $300?
- This compares with the Sharpe of 1.3 for the Trefis Reinforced Value portfolio.
- 10/02/2023
|
Here are 11 stocks Jim Cramer is watching, including Buffett's Berkshire and restaurant stocks
- Here are some of the tickers on my radar for Friday, Sept. 29, taken directly from my reporter's notebook.
- 09/29/2023
|
ResMed (RMD) Stock Jumps 3.8%: Will It Continue to Soar?
- ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 09/28/2023
|
Wall Street analysts expect the S&P 500 to rise 19% over the next 12 months. Here are their 10 favorite stocks.
- Outside of a handful of highflying technology stocks, U.S. stocks have been practically flat in 2023, but on Wall Street, some analysts remain as bullish as ever.
- 09/26/2023
|
ResMed - Trading Opportunity Now
- ResMed is the global leader in the sleep apnea market. Sales growth accelerated during COVID and again recently as a result of a product recall from its major competitor. Despite a strong last quarter the market has marked the stock down due to concerns about the long term loss of market to GLP-1 medications.
- 09/12/2023
|
ResMed Announces Participation in Upcoming Conferences
- SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced its participation in two upcoming conferences.
- 09/05/2023
|
3 Reasons ResMed's CEO Isn't Worried About Ozempic or Wegovy
- Some investors in ResMed, which makes machines for people with sleep apnea, think that effective new weight-loss drugs could shrink its addressable market. On ResMed's latest earnings call, CEO Mick Farrell laid out three reasons why he doesn't think the company will feel any impact from those drugs.
- 09/01/2023
|
Late-Summer Steals: 7 Stocks to Buy Before Fall
- With summer coming to an end, investors may want to target certain compelling stocks to buy now. Basically, the theory is the reverse of the adage, sell in May and go away.
- 08/28/2023
|
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
- Investors continue to be optimistic about ResMed (RMD), backed by the continued demand for digital health solutions.
- 08/22/2023
|
Buy the Drop: 3 Stocks to Snag After This Month's 20% Tumble
- August has been a great month for investors looking for bargain stocks to buy on the dip. The S&P 500, Dow Jones Industrial Average, and the Nasdaq 100 were down 2,1%, 2.0%, and 2.4%, respectively, for the week of Aug. 14-18.
- 08/21/2023
|
5 Blue-Chip Stocks AI Thinks Will Double Your Money by 2027
- In June, I introduced five stocks that AI predicted could double a portfolio in a year. Here's how they've done in the first month.
- 08/16/2023
|
2 Stocks That Could Grow Your Portfolio Over the Next Decade
- ResMed offers innovative solutions for people suffering from sleep apnea and other chronic diseases. Parker-Hannifin is a leader in motion control technologies and manufactures several related products.
- 08/15/2023
|
Here's Why We Think ResMed Stock Is Undervalued After An 18% Fall In A Month
- ResMed (NYSE: RMD), a medical equipment company, has seen an 18% fall in a month, underperforming the broader S&P500 index, up 1%.
- 08/11/2023
|
S&P 500 Gains and Losses Today: Stocks Lose Ground as Hiring Slows
- The S&P 500 fell 0.5% on Friday, Aug. 4, 2023, after the Labor Department's latest jobs report showed the pace of hiring slowed.
- 08/04/2023
|
ResMed's (RMD) Q4 Earnings Miss, Revenues Beat Estimates
- ResMed (RMD) records a robust sales performance in fiscal Q4 backed by the ongoing combined availability of cloud-connected AirSense 10 and AirSense 11 sleep devices.
- 08/04/2023
|
Markets Higher Midday After Upbeat Earnings, July Jobs Report
- U.S. equities were higher at midday on Friday, Aug. 4, 2023 on the back of strong earnings reports, while a cooler-than-expected July jobs report raised optimism the Fed could ease back on its campaign of rate hikes to cool inflation.
- 08/04/2023
|
ResMed (RMD) Misses Q4 Earnings Estimates
- ResMed (RMD) came out with quarterly earnings of $1.60 per share, missing the Zacks Consensus Estimate of $1.67 per share. This compares to earnings of $1.49 per share a year ago.
- 08/03/2023
|
Why Earnings Season Could Be Great for ResMed (RMD)
- ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 08/02/2023
|
ResMed (RMD) Expands Solutions Portfolio With Somnoware Buyout
- ResMed (RMD) announces the acquisition of the Somnoware diagnostic management platform.
- 07/07/2023
|
ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023
- SAN DIEGO, July 06, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2023 on Thursday, August 3, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
- 07/06/2023
|
Compound Your Wealth With ResMed
- ResMed Inc., a leader in digital health and cloud-connected medical devices, is being considered as a potential addition to a healthcare portfolio due to its consistent financial performance and innovative product ecosystem. Despite a low yield and subdued dividend growth, the company's focus on fundamentally-driven growth, top-tier products addressing modern health issues, and strong moat make it an appealing investment. With a healthy balance sheet, accelerating free cash flow, and a reasonable valuation, ResMed could be a potential wealth compounder for decades to come.
- 07/04/2023
|
ResMed's (RMD) New Buyout Aids Growth Amid Rising Costs
- ResMed's (RMD) respiratory care business witnesses continued customer uptake of bilevel and other non-invasive ventilator solutions worldwide.
- 06/15/2023
|
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
- Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.
- 06/08/2023
|
Medical Equipment Stock to Add to Your Portfolio
- Medical equipment name ResMed Inc (NYSE:RMD) is looking to snap a four-day win streak, down 0.3% at $221.33 at last glance.
- 06/06/2023
|
ResMed Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
- SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023, beginning at approximately 9:20 a.m. (Pacific Daylight Time) at the Waldorf Astoria Monarch Beach in Dana Point, CA.
- 06/05/2023
|
ZBH vs. RMD: Which Stock Should Value Investors Buy Now?
- Investors interested in stocks from the Medical - Products sector have probably already heard of Zimmer Biomet (ZBH) and ResMed (RMD). But which of these two stocks offers value investors a better bang for their buck right now?
- 05/29/2023
|
Sleep-Apnea Growth Stock Breaks Out On Record Earnings; Device Sales Surge
- Sleep-apnea device maker ResMed broke out after earnings, continuing its accelerating growth pace. The post Sleep-Apnea Growth Stock Breaks Out On Record Earnings; Device Sales Surge appeared first on Investor's Business Daily.
- 05/01/2023
|
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
- ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.
- 04/28/2023
|
ResMed Inc. (RMD) Q3 2023 Earnings Call Transcript
- ResMed Inc. (RMD) Q3 2023 Earnings Call Transcript.
- 04/27/2023
|
ResMed Gives Investors A Good Night's Sleep
- ResMed shares are selling on the expensive side of a fair value but the numbers and growth potential make us bullish on the stock. Fundamentals are strong and the forecast 6.3% annual market growth make this a stock valuable to retail value investors.
- 04/13/2023
|
ResMed to Report Third Quarter Fiscal 2023 Earnings on April 27, 2023
- SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2023 on Thursday, April 27, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
- 04/06/2023
|
3 Incredible Growth Stocks to Buy Right Now
- With the markets in flux, bargain hunters may have some prime opportunities to load up on quality names this week. Brown & Brown, Markel, and ResMed are three top-notch growth stocks worth considering in any market.
- 03/22/2023
|
Reasons Why You Should Retain ResMed (RMD) Stock For Now
- Investors are optimistic about ResMed's (RMD) Increased demand for its digital health solution.
- 03/16/2023
|
EYE vs. RMD: Which Stock Should Value Investors Buy Now?
- EYE vs. RMD: Which Stock Is the Better Value Option?
- 03/07/2023
|
Reasons Why You Should Retain ResMed (RMD) Stock For Now
- Investors are optimistic about ResMed (RMD) owing to the increased demand for its sleep and respiratory care devices.
- 02/15/2023
|
ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers
- ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.
- 02/14/2023
|
ResMed: Bulls Can Rest For Now, For Its Declining Cash Flow Performance
- ResMed continues to be a leading company in the industry, with multiple growth drivers ahead of its 2025 goals. But the outlook for ResMed doesn't look good, with YoY figures slowing and dividend payments possibly being interrupted.
- 01/30/2023
|
ESLOY vs. RMD: Which Stock Is the Better Value Option?
- ESLOY vs. RMD: Which Stock Is the Better Value Option?
- 01/27/2023
|
ResMed's (RMD) Q2 Earnings Beat Estimates, Margins Falls
- ResMed's (RMD) mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness about the importance and need for respiratory hygiene and respiratory health.
- 01/27/2023
|
ResMed Inc. (RMD) Q2 2023 Earnings Call Transcript
- ResMed Inc. (NYSE:RMD ) Q2 2023 Earnings Conference Call January 26, 2023 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO and Chairman Brett Sandercock - CFO Rob Douglas - President and COO Conference Call Participants Chris Cooper - Goldman Sachs Suraj Kalia - Oppenheimer Matthew Mishan - KeyBanc Capital Markets Steve Wheen - Jarden David Bailey - Macquarie Mike Matson - Needham & Company Craig Wong-Pan - RBC Sean Laaman - Morgan Stanley Margaret Kaczor - William Blair Matt Taylor - Jefferies Michael Polark - Wolfe Research Saul Hadassin - Barrenjoey Capital David Low - JPMorgan Dan Hurren - MST Marquee Lyanne Harrison - Bank of America Operator Hello and welcome to the ResMed Second Quarter Fiscal Year 2023 Earnings Call. At this time, all participants are in a listen-only mode.
- 01/26/2023
|
ResMed (RMD) Q2 Earnings and Revenues Surpass Estimates
- ResMed (RMD) delivered earnings and revenue surprises of 3.75% and 3.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 01/26/2023
|
ResMed to Report Second Quarter Fiscal 2023 Earnings on January 26, 2023
- SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2023 on Thursday, January 26, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
- 01/12/2023
|
Resmed is 'thinking broadly' in its supply chain globally, says CEO
- Michael Farrell of Resmed discusses the company's growth strategy after opening its largest advanced manufacturing plant in Singapore.
- 11/17/2022
|
ResMed Inc. Lets Investors Breath Easy
- ResMed is a potential opportunity for retail value investors to profit from this low-risk market leader, but there are several issues that worry us - the share price is high. The company revenue consistently grows in a niche of the healthcare device industry that will annually increase about 6% to almost $6B in revenue.
- 11/13/2022
|
ResMed: Strong Earnings Growth Supports The High Valuation, Unclear Technical Trends
- U.S. medical device equities have not been a source of safety or growth in 2022. ResMed's diversified businesses help its earnings growth outlook through 2025. The PEG ratio looks attractive.
- 11/13/2022
|
ResMed (RMD) Q1 Earnings In Line, Operating Margin Falls
- ResMed (RMD) continues to increase its access to semiconductor communications chips.
- 10/31/2022
|
ResMed Inc. (RMD) Q1 2023 Results - Earnings Call Transcript
- ResMed Inc. (NYSE:RMD ) Q1 2023 Earnings Conference Call October 27, 2022 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO & Director Brett Sandercock - CFO Rob Douglas - President, COO and Interim President, Sleep & Respiratory Care David Pendarvis - Chief Administrative Officer and Global General Counsel Conference Call Participants Steve Wheen - Jarden Matt Mishan - KeyBanc Gretel Janu - Credit Suisse Saul Hadassin - Barrenjoey Capital Dan Hurren - MST Marquee Mike Matson - Needham David Bailey - Macquarie Lyanne Harrison - Bank of America Craig Wong-Pan - RBC Chris Cooper - Goldman Sachs Suraj Kalia - Oppenheimer Margaret Kaczor - William Blair Mathieu Chevrier - Citi Steve Wheen - Jarden Limited Operator Hello, and welcome to the ResMed First Quarter Fiscal 2023 Earnings Call. At this time, all participants are in a listen-only mode.
- 10/27/2022
|
ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022
- SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2023 on Thursday, October 27, 2022, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.
- 10/13/2022
|
ResMed (RMD) Gains on Product Uptake Even as Expenses Rise
- The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.
- 09/26/2022
|
Reasons Why You Should Retain ResMed (RMD) Stock For Now
- Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.
- 08/30/2022
|
ResMed: Long-Term Thesis Remains Unchanged, Rate Buy For Compelling Value
- ResMed continues to offer compelling value after a robust set of fourth quarter earnings. RMD saw upsides at the top and bottom line relative to consensus, yet, the stock has been punished from August.
- 08/29/2022
|
ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up
- ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.
- 08/12/2022
|
Resmed, Inc. (RMD) CEO Michael Farrell on Q4 2022 Results - Earnings Call Transcript
- Resmed, Inc. (NYSE:RMD ) Q4 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Michael Farrell - CEO & Director Brett Sandercock - CFO Robert Douglas - President, COO and Interim President, Sleep & Respiratory Care Conference Call Participants Craig Wong-Pan - RBC Capital Markets Sean Laaman - Morgan Stanley Margarate Boeye - William Blair & Company David Bailey - Macquarie Research Michael Matson - Needham & Company Lyanne Harrison - Bank of America Merrill Lynch Steven Wheen - Jarden Limited David Low - JPMorgan Chase & Co. Saul Hadassin - Barrenjoey Capital Gretel Janu - Crédit Suisse Suraj Kalia - Oppenheimer Matthew Mishan - KeyBanc Capital Markets Chris Cooper - Goldman Sachs Group Dan Hurren - MST Marquee Operator Hello and welcome to the Q4 Fiscal Year 2022 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call.
- 08/11/2022
|
ResMed (RMD) Q4 Earnings Beat Estimates
- ResMed (RMD) delivered earnings and revenue surprises of 0.68% and 0.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/11/2022
|
ResMed Q4 Preview: Rebound Quarter Inbound?
- RMD has primarily exceeded the Zacks Consensus EPS Estimate. However, the company registered an 8% bottom-line miss in its latest quarter.
- 08/10/2022
|
These Are The 10 Biggest Companies Revealing Earnings Next Week
- About 56% of the S&P 500 companies have reported their quarterly earnings as of last week.
- 08/05/2022
|
ResMed to Report Fourth Quarter Fiscal 2022 Earnings on August 11, 2022
- SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2022 on Thursday, August 11, 2022, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.
- 07/14/2022
|
Reasons Why You Should Invest in ResMed (RMD) Stock Now
- Investors are optimistic about ResMed's (RMD) robust mask and device sales and continued product innovations.
- 07/06/2022
|
NUVA vs. RMD: Which Stock Should Value Investors Buy Now?
- NUVA vs. RMD: Which Stock Is the Better Value Option?
- 07/05/2022
|
7 Growth Stocks to Buy in July 2022
- The severe macroeconomic climate has led investors toward defensive plays, creating buy opportunities in the following growth stocks. The post 7 Growth Stocks to Buy in July 2022 appeared first on InvestorPlace.
- 07/04/2022
|
ResMed (RMD) Inks Deal to Acquire MEDIFOX DAN in Germany
- ResMed's (RMD) acquisition of a renowned out-of-hospital software solutions company is expected to strengthen its SaaS business.
- 06/15/2022
|
4 Big Upside Potential Picks From RBC Capital Markets
- Given the recent market moves, investors are looking for direction. Guidance from either the Federal Reserve or analysts may offer some credence, in terms of a sign.
- 06/08/2022
|
ResMed Announces Participation in the 43rd Annual Goldman Sachs Global Healthcare Conference
- SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Tuesday, June 14, 2022, beginning at approximately 1:20 p.m. (Pacific Daylight Time) at the Terranea Resort in Rancho Palos Verdes, California.
- 06/07/2022
|
ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline
- Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.
- 05/02/2022
|
ResMed Inc. (RMD) CEO Mick Farrell on Q3 2022 Results - Earnings Call Transcript
- ResMed Inc. (NYSE:RMD ) Q3 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO Brett Sandercock - CFO Rob Douglas - President and COO Jim Hollingshead - President, Sleep & Respiratory Care business David Pendarvis - Chief Administrative Officer and Global General Counsel Conference Call Participants David Low - JPMorgan Gretel Janu - Credit Suisse Lyanne Harrison - Bank of America Saul Hadassin - Barrenjoey Dan Hurren - MST Matthew Mishan - KeyBanc David Bailey - Macquarie Mike Matson - Needham & Company Suraj Kalia - Oppenheimer Operator Hello and welcome to the Q3 Fiscal Year 2022 ResMed Earnings Conference Call. My name is Kevin and I'll be your operator for today's call.
- 04/28/2022
|
ResMed (RMD) Q3 Earnings and Revenues Lag Estimates
- ResMed (RMD) delivered earnings and revenue surprises of -8.33% and 4.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 04/28/2022
|
Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More
- Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.
- 04/27/2022
|
2 Top Healthcare Stocks to Buy for the Long Haul
- Two stocks that could inflation-proof and recession-proof your portfolio.
- 04/09/2022
|
Here's Why You Should Retain ResMed (RMD) Stock for Now
- ResMed's (RMD) robust international performance and an ongoing rebound in device sales instill investor confidence in the stock.
- 03/17/2022
|
Here's Why ResMed Stock Is A Better Pick Over This Networking Equipment Company
- We believe that ResMed, a medical equipment company, currently appears to be an attractive pick over Ciena stock, a telecommunications networking equipment and software services company, with a similar revenue base, despite RMD's comparatively higher valuation. RMD stock trades at 10.5x trailing.
- 03/09/2022
|
ResMed's (RMD) SaaS Arm Strength Aids Growth, Supply Woes Stay
- ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.
- 03/07/2022
|
IHI: A Standout Performer With Equally Strong Future Growth Prospects
- IHI: A Standout Performer With Equally Strong Future Growth Prospects
- 03/05/2022
|
3 Beaten-Down Growth Stocks With More Than 50% Upside Potential
- The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions. The post 3 Beaten-Down Growth Stocks With More Than 50% Upside Potential appeared first on InvestorPlace.
- 02/25/2022
|
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
- Investors are optimistic about ResMed (RMD) on increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts.
- 02/08/2022
|
ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates
- ResMed's (RMD) Q2 earnings meet estimates, with robust demand for sleep and respiratory care devices driving the top line.
- 01/28/2022
|
ResMed Q2 Earnings Highlights: Supply Chain Constraints, Unlimited Demand Due To Competitor Recall
- ResMed Inc (NYSE: RMD) revealed a 13% Y/Y jump in Q2 FY22 revenue to $894.9 million, missing the consensus of $935.25 million. The growth was below analyst expectations as the business faced increased freight and production costs.
- 01/28/2022
|
ResMed Inc. (RMD) CEO Mick Farrell on Q2 2022 Results - Earnings Call Transcript
- ResMed Inc. (RMD) CEO Mick Farrell on Q2 2022 Results - Earnings Call Transcript
- 01/27/2022
|
ResMed (RMD) Q2 Earnings Meet Estimates
- ResMed (RMD) delivered earnings and revenue surprises of 0% and 3.92%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 01/27/2022
|
Is a Surprise Coming for ResMed (RMD) This Earnings Season?
- ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 01/25/2022
|
5 S&P Winners, 5 Losers in Monday's Premarket
- The three major U.S. equities indexes closed lower again on Friday for the fourth day in a row.
- 01/24/2022
|
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/20/2022
|
Down 9.2% in 4 Weeks, Here's Why You Should You Buy the Dip in ResMed (RMD)
- The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 01/10/2022
|
ResMed to Report Second Quarter Fiscal 2022 Earnings on January 27, 2022
- SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2022 on Thursday, January 27, 2022, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.
- 01/06/2022
|
Why ResMed (RMD) is Poised to Beat Earnings Estimates Again
- ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 12/31/2021
|
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
- Investors are optimistic about ResMed's (RMD) strong sales in its mask product offering and growing uptake of its digital health solutions.
- 12/28/2021
|
ABT or RMD: Which Is the Better Value Stock Right Now?
- ABT vs. RMD: Which Stock Is the Better Value Option?
- 12/21/2021
|
ResMed Inc.: Another Example Of Best Medical Devices Near-Term Buy - As Seen By Market-Makers
- This is an evaluation of likely coming stock prices, not an appraisal of RMD's product line or management's competitive abilities. They're already evaluated by big-$ investment analysts and portfolio managers. The buys they urge as volume “block trades” cause Market-Makers to put firm capital temporarily at risk, balancing shares supply with demand. And to hedge-protect the risks created.
- 12/05/2021
|
Here's Why You Should Retain ResMed (RMD) Stock for Now
- Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.
- 11/26/2021
|
3 Stocks to Add to Your Portfolio in the Event of a Market Downturn
- Look out for companies that can latch on to strong long-term trends to add to when the market undergoes a correction.
- 11/17/2021
|
Required Minimum Distribution Changes for 2022
- A big update to the life expectancy calculations done in required minimum distribution (RMD) tables is coming next year, and it means less money will have to be withdrawn annually. It's a potential boon on a lot of fronts, believes Tom Duncan, senior director of the advanced consulting group for Nationwide.
- 11/15/2021
|
ResMed (RMD) Q1 Earnings Top Estimates, Margins Decline
- ResMed (RMD) reports better-than-expected earnings and revenues with robust demand for sleep and respiratory care devices driving Q1 top line.
- 10/29/2021
|
ResMed Inc. (RMD) CEO Mick Farrell on Q1 2022 Results - Earnings Call Transcript
- ResMed Inc. (RMD) CEO Mick Farrell on Q1 2022 Results - Earnings Call Transcript
- 10/28/2021
|
ResMed (RMD) to Report Q1 Earnings: What's in the Cards?
- Strong customer demand and new product launches are likely to contribute to growth in the fiscal first quarter for ResMed (RMD).
- 10/20/2021
|
ResMed to Report First Quarter Fiscal 2022 Earnings on October 28, 2021
- SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2022 on Thursday, October 28, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.
- 10/07/2021
|
Here's Why You Should Retain ResMed (RMD) Stock for Now
- Investors are optimistic about ResMed (RMD) owing to new product launches in the SDB market and strong sales of mask products.
- 10/07/2021
|
ResMed Inc.: Best Price-Positioned Medical Supply Industry Stock, As Seen By Market-Makers
- ResMed Inc.: Best Price-Positioned Medical Supply Industry Stock, As Seen By Market-Makers
- 09/17/2021
|
ResMed Announces Participation in the Bank of America Global Healthcare Conference
- SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the Bank of America Global Healthcare Conference on Wednesday, September 15, 2021, beginning at approximately 5:35 p.m. (British Summer Time) via video webcast.
- 09/08/2021
|
People with Sleep Apnea Live Longer on CPAP in Large, Late-Breaking ResMed-Supported ALASKA Study Presented at ERS
- Continued PAP use linked to 39% higher chance of survival over a 3-year period Continued PAP use linked to 39% higher chance of survival over a 3-year period
- 09/08/2021
|
Chief Administrative Officer Of Resmed Makes $434.44 Thousand Sell
- David Pendarvis, Chief Administrative Officer at Resmed (NYSE:RMD), made a large insider sell on September 3, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Pendarvis sold 1,487 shares of Resmed at a price of $292.16 per share.
- 09/07/2021
|
ResMed Announces Participation in the Morgan Stanley 19th Annual Global Healthcare Conference
- SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021, beginning at approximately 1:15 p.m. (Eastern Daylight Time) via video webcast.
- 09/02/2021
|
ResMed Announces SaaS Leadership Change
- Change intended to drive rapid digital transformation, leverage full scale of cloud-connected technology platforms, and accelerate growth of ResMed's SaaS business Change intended to drive rapid digital transformation, leverage full scale of cloud-connected technology platforms, and accelerate growth of ResMed's SaaS business
- 08/25/2021
|
ResMed's (RMD) AirSense 11 to Boost Sleep Apnea Digitalization
- ResMed's (RMD) new launch will make therapy setup easier for patients and help clinicians offer care more efficiently.
- 08/19/2021
|
3 Smartest Healthcare Stocks to Buy With $1,000 Right Now
- It doesn't take a brainiac to balance risk and reward.
- 08/18/2021
|
ResMed (RMD) Hits New 52-Week High: What's Behind the Rally?
- Investors are optimistic about ResMed's (RMD) potential in digital health and its strong emphasis on product development.
- 08/17/2021
|
ResMed Launches AirSense 11 PAP Series, Advancing Digital Health in Sleep Apnea Treatment
- New digital features designed to make therapy setup and nightly use easier for patients, and help clinicians provide care more efficiently New digital features designed to make therapy setup and nightly use easier for patients, and help clinicians provide care more efficiently
- 08/16/2021
|
Final Trades: Alibaba, Resmed, Marathon Petroleum & more
- The 'Halftime Report' traders give their top picks to watch for the second half.
- 08/06/2021
|
ResMed Inc. (RMD) CEO Mick Farrell on Q4 2021 Results - Earnings Call Transcript
- ResMed Inc. (RMD) CEO Mick Farrell on Q4 2021 Results - Earnings Call Transcript
- 08/05/2021
|
ResMed (RMD) Q4 Earnings and Revenues Beat Estimates
- ResMed (RMD) delivered earnings and revenue surprises of 8.00% and 12.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2021
|
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2021
- Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
- 08/05/2021
|
6 GARP Stocks to Scoop Up for Maximum Returns
- If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
- 08/03/2021
|
5 Top Stocks to Buy With Dividends Set to Be Raised This Week
- After years of a low interest rate environment, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends that help to provide an income stream.
- 08/02/2021
|
7 Growth Stocks to Buy As Meme Stock Mania Fades
- As the craze for meme stocks fades away, investors should consider growth investing to generate big returns. Here are 7 growth stocks to buy today.
- 07/19/2021
|
ResMed to Report Fourth Quarter Fiscal 2021 Earnings on August 5, 2021
- SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2021 on Thursday, August 5, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.
- 07/15/2021
|
Grab these 3 MedTech Stocks That Outperformed S&P 500 YTD
- Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.
- 07/11/2021
|
Grab these 3 MedTech Stocks That Outperformed S&P 500 YTD
- Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.
- 07/09/2021
|
4 GARP Stocks to Scoop Up for Maximum Returns
- If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
- 07/02/2021
|
Digital Health Momentum is Here to Stay: 3 MedTech Stocks in Focus
- Here we look at three stocks, MDRX, CERN and RMD, that investors can keep a watch on the back of their robust digital health prospects.
- 06/24/2021
|
ResMed (RMD) Hits a New 52-Week High: What's Driving It?
- Investors are optimistic about ResMed (RMD) on solid digital health growth potential along with rising demand for masks and other accessories.
- 06/21/2021
|
Why ResMed Stock Exploded Higher This Week
- A competitor's misfortune could be a big opportunity for the medical device giant.
- 06/18/2021
|
Despite Philips Recall ResMed Stock Appears Fully Priced
- RMD stock is also up 179% from the levels of around $85 seen toward the end of 2017. The rise over the last three years or so is justified given the company's robust fundamentals.
- 06/17/2021
|
5 Reasons Why ResMed Gets Downgrade From BofA Securities
- Although ResMed Inc's (NYSE:RMD) long-term outlook is positive, the market seems to have over-reacted to rival Koninklijke Philips NV's (NYSE:PHG) recall notification of certain sleep and respiratory care devices for the U.S., according to BofA Securities. The ResMed Analyst: Lyanne Harrison downgraded the rating for ResMed from Neutral to Underperform, while raising the price target from $216 to $221.
- 06/16/2021
|
ResMed (RMD) Rallies as Philips Falters on Mass Product Recall
- The full U.S. launch of ResMed (RMD) AirSense 11 is expected any time in 2021, which might receive bigger market acceptance capitalizing on its current peer position.
- 06/15/2021
|
ResMed (RMD) Moves 6% Higher: Will This Strength Last?
- ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 06/15/2021
|
Lordstown, Morgan Stanley, ResMed and More Wednesday Afternoon Analyst Calls
- With the trading day about halfway over, the markets were trading sideways yet again, and it seems like the major averages may be stuck on this plateau.
- 06/09/2021
|
2 Stocks That Are Much More Likely Than AMC to Make You Rich
- Gambling can be fun, but growing sales and profits are what matter for long-term gains.
- 06/04/2021
|
ResMed Announces Participation in the William Blair 41st Annual Growth Stock Conference
- SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021, beginning at approximately 1:20 p.m. (Central Daylight Time) via video webcast.
- 05/25/2021
|
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
- Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its masks.
- 05/11/2021
|
ResMed (RMD) Q3 Earnings Surpass Estimates, Revenues Miss
- Lower device sales including weak demand for ventilators due to COVID-19 hurt ResMed's (RMD) Q3 top line.
- 04/30/2021
|
ResMed Inc. (RMD) CEO Mick Farrell on Q3 2021 Results - Earnings Call Transcript
- ResMed Inc. (RMD) CEO Mick Farrell on Q3 2021 Results - Earnings Call Transcript
- 04/29/2021
|
ResMed (RMD) to Report Q3 Earnings: What's in the Offing?
- Improvement in demand for Mask and Other accessories along with rapid adoption of digital health solution is likely to have contributed to ResMed's (RMD) Q3 growth.
- 04/23/2021
|
3 Top Value Stocks in Healthcare to Buy Right Now
- Well-known guidance from Warren Buffett can help us identify opportunities in an expensive market.
- 04/21/2021
|
4 Critical Care Device Stocks to Deflect the COVID-19 Curveball
- Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.
- 04/09/2021
|
Investing in Sleep Apnea Companies
- Three stocks to have on your radar in the healthcare space.
- 04/09/2021
|
Nyxoah Reports Full Year 2020 Results
- Nyxoah Reports Full Year 2020 Results
- 04/09/2021
|
ResMed to Report Third Quarter Fiscal 2021 Earnings on April 29, 2021
- SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2021 on Thursday, April 29, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.
- 04/08/2021
|
3 Beaten-Down MedTech Stocks to Scoop Up Amid the Pandemic
- Here are some dirt-cheap MedTech value stocks - IVC, MCK, HRC - which are expected to provide long-term gains in 2021.
- 04/01/2021
|
ResMed Stock Appears To Be Modestly Overvalued
- The stock of ResMed (NYSE:RMD, 30-year Financials) appears to be modestly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded.
- 03/23/2021
|
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
- Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its critical care products.
- 03/22/2021
|
This Company Will Fix the Hidden COVID Danger to Come
- There are long-term implications to the coronavirus pandemic that the market is not appreciating.
- 03/21/2021
|
Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy
- MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.
- 03/19/2021
|
7 Healthcare Stocks to Buy and Hold for the Long Term
- These steady, strong healthcare stocks are great picks for investors to buy and hold onto for at least the next five years. The post 7 Healthcare Stocks to Buy and Hold for the Long Term appeared first on InvestorPlace.
- 03/12/2021
|
Don't Sleep On ResMed
- ResMed reported earnings back on Jan. 28 and the stock has moved lower since then. The move lower has occurred after the company beat EPS and revenue estimates, and posted solid growth numbers from the previous year.
- 03/05/2021
|
PAHC or RMD: Which Is the Better Value Stock Right Now?
- PAHC vs. RMD: Which Stock Is the Better Value Option?
- 02/05/2021
|
ResMed (RMD) Q2 Earnings Surpass Estimates, Margins Rise
- ResMed (RMD) reported second-quarter fiscal 2021 revenues of $800 million, up 9% from a year ago.
- 01/29/2021
|
ResMed Inc. (RMD) CEO Mick Farrell on Q2 2021 Results - Earnings Call Transcript
- ResMed Inc. (RMD) CEO Mick Farrell on Q2 2021 Results - Earnings Call Transcript
- 01/28/2021
|
ResMed (RMD) Beats Q2 Earnings and Revenue Estimates
- ResMed (RMD) delivered earnings and revenue surprises of 15.57% and 3.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 01/28/2021
|
Recap: ResMed Q2 Earnings
- Shares of ResMed (NYSE:RMD) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 16.53% year over year to $1.41, which beat the estimate of $1.26.
- 01/28/2021
|
ResMed's Earnings Outlook
- On Thursday, January 28, ResMed (NYSE:RMD) will release its latest earnings report. Decipher the announcement with Benzinga's help.
- 01/27/2021
|
4 MedTech Underperformers Poised for a Turnaround in 2021
- Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.
- 01/21/2021
|
New Coronavirus Strain to Keep Telehealth Stocks in Demand
- Telemedicine is here to stay as the new coronavirus strain triggers a fear psychosis at large, thereby retaining solid demand for telehealth stocks.
- 01/19/2021
|
QDEL vs. RMD: Which Stock Is the Better Value Option?
- QDEL vs. RMD: Which Stock Is the Better Value Option?
- 01/14/2021
|
Outset Medical Appoints Karen Drexler to Board of Directors
- SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, is bolstering its board of directors with the appointment of Karen Drexler. Drexler currently serves on the boards of ResMed (NYSE: RMD), a $31B data-driven sleep and respiratory market leader; VIDA Diagnostics, developer of AI-powered lung intelligence and imaging solutions; and Tivic Health, a bioelec
- 01/12/2021
|
5 Soaring MedTech Stocks to Buy for More Growth in 2021
- We have selected five MedTech growth stocks with further rooms for improvement in 2021.
- 12/30/2020
|
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
- Investors continue to be optimistic about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
- 12/30/2020
|
5 Top Stocks With Attractive Sales Growth to Keep an Eye on
- A steady sales growth is key to survival for any company. Let's check Broadcom (AVGO), PennyMac Financial (PFSI), ResMed (RMD) Williams-Sonoma (WSM) & Parker-Hannifin (PH) as these are likely to witness solid sales growth.
- 12/24/2020
|
4 GARP Stocks to Scoop Up for Maximum Returns
- If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
- 12/18/2020
|
5 MedTech Stocks That Have Outperformed the Industry in 2020
- Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.
- 12/17/2020
|
Final Trades: Home Depot, Zimmer Holdings, Tractor Supply & more
- The "Halftime Report" traders give their top picks to watch for the second half.
- 12/16/2020
|
Tandem Diabetes Care Appoints Raj Sodhi to Board of Directors
- SAN DIEGO--(BUSINESS WIRE)---- $TNDM--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rajwant (Raj) Singh Sodhi as an independent member of its board of directors effective January 1, 2021. He will succeed Edward Cahill, who has served as a board member for the Company since May 2009. Mr. Sodhi is president of the software as a service (SaaS) business at ResMed (NYSE: RMD, ASX: RMD). He brings to the Tandem board mo
- 12/14/2020
|
Here's Why You Should Add ResMed (RMD) to Your Portfolio
- Investors continue to be positive about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
- 11/26/2020
|
ResMed CEO on digital health, treating patients outside the hospital
- ResMed CEO Michael Farrell broke down how the medical equipment benefits from the emerging digital medicine space.
- 11/20/2020
|
4 GARP Stocks to Scoop Up for Maximum Returns
- If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
- 11/19/2020
|
ResMed Underscores the Importance of Good Sleep with #WakeUpToGoodSleep Campaign
- NEW DELHI--(BUSINESS WIRE)---- $RMD #sleep--ResMed's #WakeUpToGoodSleep campaign highlights the growing and largely unidentified sleep disorders in India and the treatment options available.
- 11/05/2020
|
ResMed Shows Healthy Improvement Amid Top-Notch Profit Growth
- ResMed shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. The post ResMed Shows Healthy Improvement Amid Top-Notch Profit Growth appeared first on Investor's Business Daily.
- 11/02/2020
|
ResMed's (RMD) CEO Mick Farrell on Q1 2020 Results - Earnings Call Transcript
- ResMed's (RMD) CEO Mick Farrell on Q1 2020 Results - Earnings Call Transcript
- 10/29/2020
|
